source
- BrainChild secures $116M to advance CAR-T therapies for rare pediatric brain tumorsBrainChild Bio, a Seattle‑based biotech spun out of Seattle Children’s Hospital, announced it has raised $116 million in venture financing. The capital will fund the development of its CAR‑T cell t…
- Bristol Myers reports Phase 2 success for GPRC5D‑directed CAR‑T therapyBristol Myers announced positive Phase 2 results for its GPRC5D‑directed CAR‑T therapy aimed at treating multiple myeloma. The study demonstrated encouraging efficacy signals, adding to the growing…